Sujal Shah, CymaBay CEO (Jeff Rumans)
CymaBay looks to raise $85M as liver drug's PhIII readout looms
Bay Area biotech CymaBay Therapeutics is looking to start the year with more cash in its pockets.
CymaBay announced on Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
